Lundbeck’s Vyepti gets Japan marketing authorization
Japan’s MHLW granted marketing authorization for Lundbeck’s Vyepti (eptinezumab) to help prevent migraine attacks in adults, citing global Phase III and Japan-specific studies.
Japan’s Ministry of Health, Labour and Welfare granted marketing authorization to Lundbeck’s Vyepti (eptinezumab) for the prevention of migraine attacks in adults. The approval was supported by global Phase III data and Japan-specific studies.